What the FDA labels say about taking them together
Gemfibrozil and rosuvastatin
Gemfibrozil's FDA label of April 10, 2026 names rosuvastatin in its drug interactions section, and rosuvastatin's label names gemfibrozil too. The gemfibrozil label: “Avoid concomitant use of LOPID with rosuvastatin.”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the gemfibrozil label say about rosuvastatin?
Gemfibrozil label, drug interactionsAvoid concomitant use of gemfibrozil with rosuvastatin.
Gemfibrozil label, warningsOATP1B1 substrates – Gemfibrozil is an inhibitor of organic anion-transporter polyprotein (OATP) 1B1 and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan).
Source: FDA drug label (Lopid, NDA018422), Parke-Davis Div of Pfizer Inc, effective May 21, 2026 (SPL set c48855b7-215e-453b-b3b1-a0f9dee7221f), via openFDA
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about gemfibrozil?
Rosuvastatin label, drug interactionsGemfibrozil Prevention or Management: Avoid concomitant use of gemfibrozil with rosuvastatin.
Rosuvastatin label, warnings and precautionsSteps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis The concomitant use of rosuvastatin with cyclosporine or gemfibrozil is not recommended.
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Rosuvastatin | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | $0.0692 per tablet 40 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once